A little help from residual β cells has long-lasting clinical benefits is a research paper published in Journal of Clinical Investigation (2021). On theSindex it has a DataRank of 0. It has been cited 15 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIDDK NIH HHS
Grant: R01 DK057846
NIDDK NIH HHS
Grant: U01 DK085466
NCATS NIH HHS
Grant: UL1 TR001863
NIDDK NIH HHS
Grant: R43 DK116577
NIDDK NIH HHS
Grant: P30 DK045735
National Institutes of Health
Grant: 3R01DK057846-10S1
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
National Institutes of Health
Grant: 5U01DK085466-02
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)
FWCI
1.67
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals